Patent Assignment
Reel/Frame 055935/0864
Assignment of Assignor's Interest
Recorded: 2021-04-15
Pages: 5
Assignor
DYNAVAX TECHNOLOGIES CORPORATION
Executed: 2020-07-31
Assignee
SUREFIRE MEDICAL, INC. D/B/A TRISALUS LIFE SCIENCES
6272 WEST 91ST AVENUE, WESTMINSTER, COLORADO, 80031
Covered Property
(1)
Combination Including a Cpg-C Type Oligonucleotide and a Pd-1 Antagonist for Treating Breast Cancer
Application:
17/229,856 →
Publication:
US 2021/0315991
Related Assignments
(5)
Other recorded transfers of the patent in this record — the chain of ownership.
Assignment of Assignor's Interest
Apr 15, 2021
From: JANSSEN, ROBERT S.; GAMELIN, ERICK
To: DYNAVAX TECHNOLOGIES CORPORATION
Reel/Frame 055934/0939 →
Assignment of Assignor's Interest
Apr 15, 2021
From: SOLIMAN, HATEM
To: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
Reel/Frame 055935/0316 →
Assignment of Assignor's Interest
Apr 15, 2021
From: ESSERMAN, LAURA J.; CHIEN, AMY JO
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 055950/0171 →
Security Interest
Apr 30, 2024
From: TRISALUS LIFE SCIENCES, INC.
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 067274/0733 →
Change of Name
Aug 29, 2024
From: SUREFIRE MEDICAL, INC.
To: TRISALUS LIFE SCIENCES, INC.
Reel/Frame 068808/0050 →